Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients

• DOI: 10.1016/j.ejca.2005.11.012
• Publication Date: 2006-01-19T19:07:22Z
• Authors: Jonas Cicenas; Patrick Urban; Willy Küng; Vincent Vuaroqueaux; Martin Labuhn; Edward Wight; Urs Eppenberger; Serenella Eppenbe...
• Keywords: Immunoassay; Receptor, ErbB-2; Breast Neoplasms; Prognosis; Disease-Free Survival; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Cell Line, Tumor; Luminescent Measurements; Humans; Tyrosine; Female; Phosphorylation

ERBB2 (HER2/Neu) gene amplification and overexpression is associated with increased risk of metastases and shorter survival in breast cancer. Tyrosine 1248 is a major phosphorylation site of ERBB2 and reflects the activation status of the receptor. The aim of this study was to investigate the relationships between quantitative levels of pY1248-ERBB2 (p-ERBB2) and the expression of epidermal growth factor receptor (EGFR)-family members, and whether p-ERBB2 could provide additional prognostic value compared with established prognostic markers. For this purpose we developed a highly sensitive chemiluminescence-linked immunoassay (CLISA) and detected p-ERBB2 levels in 70 primary breast cancer biopsies. Phosphorylated ERBB2 correlated with EGFR and ERBB2, and inversely with oestrogen receptor (ER), progesterone receptor (PgR) and ERBB4 expression levels. Additionally, p-ERBB2 was associated with poor clinical outcome in univariate and multivariate Cox regression analysis. Further studies are needed to evaluate the predictive value of p-ERBB2.